Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study Evaluating Activity of Zenocutuzumab (MCLA-128) in Patients With or Without Molecularly Defined Cancers

NCT05588609 is registered in ClinicalTrials.gov with Partner Therapeutics, Inc. as lead sponsor.

NCT NCT05588609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05588609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study Evaluating Activity of Zenocutuzumab (MCLA-128) in Patients With or Without Molecularly Defined Cancers
Lead sponsor
Partner Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
November 17, 2022
Completion date
July 3, 2025
Enrollment
13 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer, nsclc harboring nrg1 fusion